| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst David Larsen maintains BrightSpring Health (NASDAQ:BTSG) with a Buy and raises the price target from $30 to $41.
UBS analyst A.J. Rice maintains BrightSpring Health (NASDAQ:BTSG) with a Buy and raises the price target from $35 to $42.
BrightSpring Health (NASDAQ:BTSG) raises FY2025 sales outlook from $12.400 billion-$12.700 billion to $12.500 billion-$12.800 b...
BrightSpring Health (NASDAQ:BTSG) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of...
BrightSpring. No shares are being sold by BrightSpring in the offering. The Selling Stockholders will receive all of the procee...
BrightSpring Health (NASDAQ:BTSG) raises FY2025 sales outlook from $12.200 billion-$12.600 billion to $12.400 billion-$12.700 b...
BrightSpring Health Services, Inc. (NASDAQ:BTSG) ("BrightSpring" or the "Company"), a leading provider of home ...